MAP2K7 and metastatic melanoma: In addition to anti-CTLA-4 antibodies, several anti-PD-1/PD-L1 antibodies were tested in combination with BRAF/MEK inhibitors in metastatic melanoma (NCT01656642, NCT02130466, and NCT02818023).